Printer Friendly

Prevalence and Clinical Characteristics of Itch in Vitiligo and Its Clinical Significance.

1. Introduction

Vitiligo is a common acquired hypopigmentary disorder, affecting up to 2% of the general population [1]. The pathogenesis of vitiligo is still not fully elucidated. However, it is postulated that vitiligo is a multifactorial, polygenic disorder, with a complex pathogenesis. Several theories on the etiology of vitiligo have emerged, for example, genetic hypothesis, autoimmune hypothesis, defects of melanocyte adhesion, neurogenic damage, and biochemical damage [2-7].

Classically vitiligo is manifested as well-defined, irregular-shaped, depigmented macules or patches. The lesions enlarge centrifugally over time, and the rate may be slow or rapid. Erythematous border is occasionally observed at the vitiliginous lesions, which is referred to as inflammatory vitiligo or vitiligo with raised inflammatory borders.

Vitiligo is usually considered as an asymptomatic dermatosis. However, itch was occasionally mentioned in some vitiligo patients. According to a study by Levai, vitiligo affected patients, with or without the presence of irritated skin lesions, can suffer from itch prior to the appearance of depigmented patches [8]. Furthermore, published data on the prevalence and characteristics of itch in vitiligo are very limited. The objective of this study was to determine the prevalence and factors influencing itch in patients with vitiligo.

2. Materials and Methods

2.1. Study Design and Patient Eligibility. This questionnaire-based cross-sectional study was conducted from January 2016 to December 2016 at university-based hospital (Ramathibodi Hospital, Mahidol University, Bangkok, Thailand). Patients over 18 years of age affected with all types of vitiligo attending the dermatology outpatient department were enrolled in this study. They were excluded if they refused to participate in the study. Patients unable to read or understand the questionnaire were also excluded. The study was approved by institutional review board of Faculty of Medicine Ramathibodi Hospital, Mahidol University (protocol number 125813). The study protocol followed the guidelines of the 1964 Helsinki declaration. All patients had obtained the inform consent prior to enrollment.

2.2. Questionnaire Details. The questionnaire was divided into 2 parts. The first was self-reported information from patients, namely, demographic data (e.g., age, gender, weight, height, and income), family history of vitiligo, age of onset of vitiligo, initial location of the lesion, factors influencing the disease, Koebner phenomenon (KP) type 1, disease activity, and dermatology life quality index (DLQI). "True itch" refers to pruritus occurring before or after development of vitiliginous lesion but not related to treatment (e.g., topical medications, phototherapy). If it is present, patients then would be questioned about the different dimensions of itch including characteristic, aggravating and alleviating factors, the relationship of itch and the development of lesion, disease activity during the past 6 months, and sleep and activity disturbance. A 10-point visual analog scale (VAS) was used to grade itch intensity. Patients were also asked to compare the magnitude of itch to their past itch experience from a common itch-related condition, namely, insect bite. The VAS scale was categorized into the terms "mild itch" (VAS > 0to <3.0), "moderate itch" (VAS [greater than or equal to] 3.0 to <7.0), and "severe itch" (VAS [greater than or equal to] 7.0 to 10).

The second part of the questionnaire was physicianreported information regarding physical examination and laboratory data of the participants, for example, Fitzpatrick skin type, other skin and systemic diseases, percentage of body surface area (BSA) involvement using the rule of nines as in burn assessment, type of vitiligo, leukotrichia, KP, anti-microsomal, anti-thyroglobulin, and anti-nuclear antibody (ANA), thyroid-stimulating hormone (TSH), free triiodothyronine (free T3), and free thyroxine (free T4).

KP was classified into 3 types based on the Vitiligo European Task Force group [9]. Type 1 KP is defined as the diagnosis of KP based on history (i.e., depigmentation after skin trauma). Type 2A KP is classified as patients having vitiligo localized to areas of repeated pressure or friction (e.g., elbows, knee, and knuckle) and type 2B KP is characterized by depigmented lesions clearly induced by trauma (i.e., artefactual lesions, punctiform, and crenate). Type 3 KP is defined as experimentally induced KP.

2.3. Assessment and Statistical Analyses. Statistical analyses were performed using computer software (Stata version 14, StataCorp., College Station, Texas) for Windows. Categorical variables were expressed as percentages. Continuous variables (e.g., age, BSA involvement, and VAS) were expressed in terms of mean [+ or -] standard deviation or median (range). Comparison of categorical variables was performed using the chi-squared test. The paired f-test or Wilcoxon signed-rank test was used to compare continuous data between two dependent samples. A p value of 0.05 or less was considered statistically significant.

3. Results

3.1. Patients' Demographic Data. A total of 402 patients were enrolled. There were 144 male and 258 female participants in the study. The mean age of patients was 45.43 ([+ or -]16.19). The median duration of vitiligo was 7 years (0.8-59). Most patients had less than 20% of BSA involvement. Regarding type of vitiligo, nonsegmental vitiligo was the most common in this study (N = 321,79.9%) followed by segmental vitiligo and focal vitiligo, 64 (15.9%) and 17 (4.2%), respectively. The demographic data and baseline characteristics of patients affected by vitiligo with and without itch are shown in Table 1. There were no significant differences in demographic characteristics between the two groups.

3.2. Prevalence of Itch and Itch Characteristics. Overall, itch was found in 81 patients with vitiligo (20.2%). Among vitiligo subtypes, itch was most commonly presented in focal vitiligo (29.4%), followed by segmental vitiligo (20.3%) and nonsegmental vitiligo (19.6%), respectively. The presence of itch significantly correlated with initial lesion located on the trunk (p < 0.001) (Table 1). Patients described the sensory qualities of itch as tingling (82.7%), crawling (18.5%), and burning (18.5%). Other itch sensations (e.g., pinching, electric discharge, and tickling) were rarely reported (<3%). Approximately 21% of patients who suffered from itch reported having at least two sensory qualities (Table 2). Among them, women were reported to have crawling sensation more frequently than men (7.4% in men versus 24.1% in women, p = 0.069) (Table 3).

3.3. Severity of Itch. The median intensity of itch on 10-point VAS was 5 (1-10), a magnitude equivalent to pruritus caused by insect bite reaction through the patients' experiences. Severe itch was reported in 23 patients (28.4%). Itch of moderate and mild intensity was documented in 35 (43.2%) and 23 (28.4%) of patients, respectively (Table 2). Itch was described to be more intense in females when compared to the male counterpart (33.3% versus 18.6%, p = 0.291) (Table 3).

As for the burden of itch among affected patients, the median DLQI score in the itch group was significantly higher than those without it (7 versus 5, p < 0.001) (Table 1). Daily activity disturbance was found in 49 patients (60.5%) and sleep disturbance was found in 32 patients (39.5%). Thirty patients (37%) reported moderate to severe activity disturbance. This was significantly more among female patients (p = 0.033) (Table 3). The magnitude of activity disturbance correlated significantly with itch intensity (p = 0.002) (Figure 1).

3.4. Relationship of Itch and the Development of Lesions. Itch preceded the onset of vitiliginous lesions in 39 patients (48.1%) with the median of 3 days (1-60) prior to the development of the lesion. Thirty-seven patients (45.7%) reported that itch occurred after the appearance of vitiliginous lesion, with the median of 1 day after the onset (0.5-30) (Table 2). In 5 out of 81 patients who had itch (6.2%), the relationship between onset of itch and the lesion development could not be determined.

3.5. Aggravating Factors and Alleviating Factors. Common aggravating factors of itch were skin dryness (58.0%), hot environment (49.4%), and sunlight (24.7%). Topical corticosteroids (55.6%) were the most common itch-alleviating factor followed by shower (38.2%). Oral antihistamine improved itch in some patients (9.9%). Cold environment was found to both aggravate and alleviate itch in 16.1% and 25.9% of patients, respectively. Factors that aggravated and relieved itch were shown in Table 2.

3.6. Itch and the Disease Activity. In this study, KP was found in 56% of patients. The presence of KP types I and II tends to be more common in vitiligo patients with itch compared to those without. This is especially true for KP type IIb (p = 0.056) (Table 4). Among 32 patients with itch and Kp type IIb, 78.1% had active disease (i.e., lesion progression and/or newly developed lesion), while 21.9% had stable disease within the past 6 months (p = 0.001) (Figure 2).

4. Discussion

Itch is a common symptom of many dermatological diseases. It may originate in the skin or nervous system. Clinically, itch can be classified into itch associated with skin disorders (e.g., xerosis, atopic dermatitis, urticaria, psoriasis, and arthropod bite), itch associated with systemic diseases (e.g., chronic liver disease, end stage renal failure), neuropathic itch (e.g., notalgia paresthetica, postherpes zoster neuropathy), and psychogenic itch. However, itch associated with vitiligo is rarely mentioned in the literature.

In this study, the prevalence of itch in vitiligo patients is up to 29.4% depending on vitiligo subtype. The prevalence of itch in this study is higher than a previous report. According to a study by Levai, 44% of vitiligo patients had a history of prior skin disease in an area of depigmentation, 15% had depigmentation in areas of constant pressure or irritation, and 10% complained of itching without prior history of skin disease or trauma [8]. The higher prevalence of itch in our study could be due to the differences in the study population. Itch in several patients with depigmented lesions described by Levai, in fact, could possibly be from chemical leukoderma and postinflammatory depigmentation and, thereby, may not represent the exact prevalence of itch in true vitiligo patients.

Itch can occur as a consequence of treatment, for example, topical mediation and phototherapy. We have excluded this group from the study. Moreover, certain systemic disease associated with vitiligo could potentiate itch such as hyperthyroidism, hypothyroidism, diabetes mellitus, allergic rhinitis, or asthma. According to our study, there were no significant differences regarding the prevalence of these conditions among patients with and without itch. Therefore, we postulate that itch in vitiliginous lesion is a manifestation of vitiligo itself.

The pathogenesis of itch in vitiligo remains unclear. However, the possible concept of itch in many dermatological diseases is focused on neurogenic inflammation and mediators such as neuropeptides released from dermal nerve endings induced byvarious stimuli. There are many evidences to support the hypothesis of inflammation in vitiliginous lesion. According to recent studies, cell-mediated immunity in vitiligo was demonstrated by the presence of CD8+ T cells in suction blistering skin, perilesional skin, and the blood of vitiligo patients. Moreover, vitiliginous lesion demonstrated lower CD4+ to CD8+ lymphocytes ratio compared to nonlesional skin [10-13]. Other parameters such as cytokines and regulatory T cells may also play major roles in vitiligo pathogenesis [14]. An increase in tumor necrosis factor alpha (TNF-[alpha]), interferon-gamma (IFN-[gamma]), and interleukin- (IL-) 1 compared to healthy skin suggests that vitiligo is mediated by cytotoxic T cells and T helper cell-1 (Th1) response [15-18]. In segmental vitiligo, dysfunction of the sympathetic nervous system can restrain melanin production and lead to depigmentation [19]. All these findings may illustrate neurogenic inflammatory mechanism of itch in vitiligo. However, it is unclear whether primary immune response targets normal melanocytes or ifimmune activation is triggered by damaged melanocytes through exogenous or endogenous insult. Further studies are needed to explain the complex mechanisms of itch in vitiligo.

There are several methods to assess the intensity of itch. In this study, the ratings were based on patients' 10-point VAS self-evaluation scale. According to our data, the median intensity of itch in was 5 (median VAS = 5). Our patients rated this equivalent to the severity of itch caused by arthropod bite. However, the comparison itch intensity in different types of dermatoses is very difficult and no direct assessment has been performed. Based on previous studies, using a similar VAS score, the intensity of itch in atopic dermatitis, psoriasis, and lichen planus was 4.8, 6.3, and 6.9, respectively [20-22]. In this study, 71.6% of patients with itch reported moderate or severe intensity. Approximately 60% of vitiligo patients with itch had daily activity disturbance and 39.5% had sleep disturbance. This may result in psychological distress and potentiate the severity of several dermatoses including vitiligo. Therefore, we emphasized the importance of itch in vitiligo which remains underrecognized.

Among the clinical variants of vitiligo, pruritus was more common in focal vitiligo and significantly correlated with initial truncal distribution. Our finding supports previous evidence on the variations in area-specific innervation density and pruritic mediator release in different anatomical sites of the body [23, 24]. In addition, the nerves which supply sensation to the upper trunk emerge from the 2nd to 6th thoracic segments of spinal cord. They run a long course up through the thick muscles of the back and make a right-angled turn before reaching the skin. These nerves appear to be vulnerable to compression or traction and lead to the symptom of itch [25]. Although our data indicates that the presence of initial lesion on trunk is highly associated with itch (p = 0.001), the numbers are too small to make a convincing support that the location is the key issue for itch. When compared to other itchy dermatosis, pruritus in lichen planus tends to be more prominent on the extremities, while psoriatic patients experience itch on both the trunk and lower extremities [22,26].

Regarding factor influencing itch, skin dryness was identified as an aggravating factor of pruritus by 58% of the patients. However, the presence of skin dryness did not correlate with the degree of itch which is consistent with other pruritic dermatoses [27-29]. Several factors such as alteration stratum corneum surface lipid, water metabolism, pH, and cytokine levels may contribute to the sensation of itch [30,31].

Hot environment and sunlight were identified as an important aggravating factor of itch in our vitiligo patients, possibly from high temperatures in our tropical climate. It was suggested that heat can increase itch sensation by its direct effect on dermal nerve endings or by indirect effect on neuroautonomic mechanism via sweating, as both itch and sweating are mediated by C nerve fibers [32, 33]. According to recent data, heat stimulated itch through the activation of transient receptor potential cation channel subfamily vanilloid type 1 (TRPV1), the calcitonin gene-related peptide, the vesicular glutamate transporter 2, and accumulation of artemin [34]. Further investigations are needed to validate whether these receptors are involved in the pathogenesis of itch in vitiligo.

The most common antipruritic treatment used was topical steroids. Due to the evidence of inflammatory cell infiltration and certain cytokines in vitiliginous lesion, antiinflammatory therapies may result in cessation of itch. Moisturizers in topical medication may have a contributing benefit in reducing the itch. In addition, cold environment and shower were found to alleviate itch in vitiligo. These observations support a role for the cold-sensitive transient receptor potential melastatin-8 (TRPM8) ion channel, the major receptor for sensing cold environmental, in the modulation of pruritus [35]. In contrast to other pruritic dermatoses, the role of antihistamines in relieving itch is questionable in vitiligo. Only a few of our patients responded to oral antihistamines.

According to a study by Van Geel et al., higher disease activity was found in KP1-positive and KP2B-positive vitiligo patients [9]. In our study, there is a tendency towards itch being more prevalent in patients presenting with KP type 2B (Table 4). Therefore, it could be implied that the presence of itch may warrant active stage of vitiligo especially with the presence of KP type IIb. A possible explanation to this phenomenon is that the inflammatory process of active vitiligo promotes pruritogenic cytokines and induces itch.

There are some limitations in our study. Firstly, recall bias associated with self-responded questionnaire may influence the results. Secondly, as patients were gathered from university-based hospital, there is a possibility of subject selection election bias. Thirdly, our study involved patient subjected evaluation; an objective assessment was not performed. Finally, further studies regarding the neurophysiology of itch including mechanism of itch in vitiligo are necessary.

In conclusion, this is the first step towards enhancing comprehensive knowledge regarding itch in vitiligo. As dermatologists, it is prudent to acknowledge that pruritus is an important aspect of vitiligo. Prompt detection to provide early treatment is mandatory in patients with active vitiligo.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.


[1] A. Alikhan, L. M. Felsten, M. Daly, and V. Petronic-Rosic, "Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up," Journal of the American Academy of Dermatology, vol. 65, no. 3, pp. 473-491, 2011.

[2] R. E. Boissy and R. A. Spritz, "Frontiers and controversies in the pathobiology of vitiligo: Separating the wheat from the chaff'," Experimental Dermatology, vol. 18, no. 7, pp. 583-585, 2009.

[3] I. C. le Poole and R. M. Luiten, "Autoimmune etiology of generalized vitiligo," Current Directions in Autoimmunity, vol. 10, pp. 227-243, 2008.

[4] Y. Gauthier, M. C. Andre, and A. Taieb, "A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy?" Pigment Cell Research, vol. 16, no. 4, pp. 322-332, 2003.

[5] M. R. Namazi, "Neurogenic dysregulation, oxidative stress, autoimmunity, and melanocytorrhagy in vitiligo: can they be interconnected?" Pigment Cell Research, vol. 20, no. 5, pp. 360-363, 2007.

[6] M. L. DellAnna and M. Picardo, "A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo," Pigment Cell Research, vol. 19, no. 5, pp. 406-411, 2006.

[7] M. Rashighi and J. E. Harris, "Vitiligo Pathogenesis and Emerging Treatments," Dermatologic Clinics, vol. 35, no. 2, pp. 257-265, 2017.

[8] M. Levai, "The Relationship of Pruritus and Local Skin Conditions to the Development of Vitiligo," A. M. A. Archives of Dermatology, vol. 78, no. 3, pp. 372-377, 1958.

[9] N. Van Geel, R. Speeckaert, J. De Wolf et al., "Clinical significance of Koebner phenomenon in vitiligo," British Journal of Dermatology, vol. 167, no. 5, pp. 1017-1024, 2012.

[10] J. P. Strassner, M. Rashighi, M. Ahmed Refat, J. M. Richmond, and J. E. Harris, "Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity," Journal of the American Academy of Dermatology, vol. 76, no. 5, pp. 847-855, 2017.

[11] J. G. van den Boorn, D. Konijnenberg, T. A. M. Dellemijn et al., "Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients," Journal of Investigative Dermatology, vol. 129, no. 9, pp. 2220-2232, 2009.

[12] N. A. C. van Geel, I. G. Mollet, S. De Schepper et al., "First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi," Pigment Cell and Melanoma Research, vol. 23, no. 3, pp. 375-384, 2010.

[13] N. Oiso, T. Suzuki, K. Fukai, I. Katayama, and A. Kawada, "Nonsegmental vitiligo and autoimmune mechanism," Dermatology Research and Practice, vol. 2011, Article ID 518090, 7 pages, 2011.

[14] Y. Kotobuki, A. Tanemura, L. Yang et al., "Dysregulation of melanocyte function by Th17-related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris," Pigment Cell and Melanoma Research, vol. 25, no. 2, pp. 219-230, 2012.

[15] S. Moretti, A. Spallanzani, L. Amato, G. Hautmann, I. Gallerani, and P. Fabbri, "Vitiligo and epidermal microenvironment: possible involvement of keratinocyte-derived cytokines," Archives of Dermatology, vol. 138, no. 2, pp. 273-274, 2002.

[16] S. Moretti, A. Spallanzani, L. Amato et al., "New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions," Pigment Cell Research, vol. 15, no. 2, pp. 87-92, 2002.

[17] N.-H. Kim, S. Jeon, H.-J. Lee, and A.-Y. Lee, "Impaired PI3K/Akt activation-mediated NF-[kappa]B inactivation under elevated TNF-[alpha] is more vulnerable to apoptosis in vitiliginous keratinocytes," Journal of Investigative Dermatology, vol. 127, no. 11, pp. 2612-2617, 2007.

[18] A. Bird, U. Kisa, G. S. Kurtipek et al., "Increased tumor necrosis factor alpha (TNF-[alpha]) and interleukin 1 alpha (IL1-[alpha]) levels in the lesional skin of patients with nonsegmental vitiligo," International Journal of Dermatology, vol. 45, no. 8, pp. 992-993, 2006.

[19] G. F. Mohammed, A. H. A. Gomaa, and M. S. Al-Dhubaibi, "Highlights in pathogenesis of vitiligo," World Journal of Clinical Cases, vol. 3, no. 3, pp. 221-230, 2015.

[20] M. A. Gupta and A. K. Gupta, "Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis," British Journal of Dermatology, vol. 139, no. 5, pp. 846-850, 1998.

[21] M. A. Gupta, A. K. Gupta, S. Kirkby et al., "Pruritus in Psoriasis: a prospective study of some psychiatric and dermatologic correlates," Archives of Dermatology, vol. 124, no. 7, pp. 1052-1057, 1988.

[22] K. Welz-Kubiak, A. Reich, and J. Szepietowski, "Clinical Aspects of Itch in Lichen Planus," Acta Dermato Venereologica, vol. 97, no. 4, pp. 505-508, 2017.

[23] M. Ozawa, K. Tsuchiyama, R. Gomi, F. Kurosaki, Y. Kawamoto, and S. Aiba, "Neuroselective transcutaneous electric stimulation reveals body area-specific differences in itch perception," Journal of the American Academy of Dermatology, vol. 55, no. 6, pp. 996-1002, 2006.

[24] I. Besne, C. Descombes, and L. Breton, "Effect of age and anatomical site on density of sensory innervation in human epidermis," Archives of Dermatology, vol. 138, no. 11, pp. 1445-1450, 2002.

[25] N. K. Shumway, E. Cole, and K. H. Fernandez, "Neurocutaneous disease: Neurocutaneous dysesthesias," Journal of the American Academy of Dermatology, vol. 74, no. 2, pp. 215-228, 2016.

[26] G. Yosipovitch, A. Goon, J. Wee, Y. H. Chan, and C. L. Goh, "The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis," British Journal of Dermatology, vol. 143, no. 5, pp. 969-973, 2000.

[27] G. Yosipovitch, "Dry skin and impairment of barrier function associated with itch - New insights," International Journal of Cosmetic Science, vol. 26, no. 1, pp. 1-7, 2004.

[28] S. Seidenari and G. Giusti, "Objective assessment of the skin of children affected by atopic dermatitis: A study of pH, capacitance and TEWL in eczematous and clinically uninvolved skin," Acta Dermato-Venereologica, vol. 75, no. 6, pp. 429-433, 1995.

[29] G. Yosipovitch, J. Reis, E. Tur, E. Sprecher, D. Yarnitsky, and G. Boner, "Sweat secretion, stratum corneum hydration, small nerve function and pruritus in patients with advanced chronic renal failure," British Journal of Dermatology, vol. 133, no. 4, pp. 561-564, 1995.

[30] P M. Elias and R. Ghadially, "The aged epidermal permeability barrier: Basis for functional abnormalities," Clinics in Geriatric Medicine, vol. 18, no. 1, pp. 103-120, 2002.

[31] H. Nojima, M. I. Carstens, and E. Carstens, "c-fos expression in superficial dorsal horn of cervical spinal cord associated with spontaneous scratching in rats with dry skin," Neuroscience Letters, vol. 347, no. 1, pp. 62-64, 2003.

[32] G. Yosipovitch, K. Fast, and J. D. Bernhard, "Noxious heat and scratching decrease histamine-induced itch and skin blood flow," Journal of Investigative Dermatology, vol. 125, no. 6, pp. 1268-1272, 2005.

[33] F. E. Cormia, "Experimental histamine pruritus. I. Influence of physical and psychological factors on threshold reactivity," The Journal of investigative dermatology, vol. 19, no. 1, pp. 21-34, 1952.

[34] H. Murota and I. Katayama, "Evolving understanding on the aetiology of thermally provoked itch," European Journal of Pain, vol. 20, no. 1, pp. 47-50, 2016.

[35] O. C. Lucaciu and G. P Connell, "Itch sensation through transient receptor potential channels: a systematic review and relevance to manual therapy," Journal of Manipulative and Physiological Therapeutics, vol. 36, no. 6, pp. 385-393, 2013.

Vasanop Vachiramon, Woranit Onprasert, Sarawin Harnchoowong, and Kumutnart Chanprapaph

Division of Dermatology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Correspondence should be addressed to Vasanop Vachiramon;

Received 16 May 2017; Revised 26 June 2017; Accepted 3 July 2017; Published 30 July 2017

Academic Editor: Adam Reich

Caption: Figure 1: Correlation of intensity of pruritus and degree of activity disturbance.
Table 1: Demographic data and clinical characteristics of vitiligo
patients with and without itch.

Characteristics                    Itch           Nonitch        P

Age, mean [+ or -] SD          46.5 [+ or -]   45.2 [+ or -]   0.519
  (years)                           16             16.2
Gender, n (%)                                                  0.601
  (i) Male                       27 (33.3)      117 (36.4)
  (ii) Female                    54 (66.7)      204 (63.6)
Onset (years), median            37 (0-72)       36 (1-75)     0.438
Duration of vitiligo             6 (0-59)       7 (0.83-51)    0.456
  (years), median (range)
Family history of                17 (21.0)       73 (22.7)     0.735
  vitiligo, n (%)
Family history of thyroid        10 (12.4)       40 (12.5)     0.978
  and autoimmune disease,
  n (%)
Leukotrichia, n (%)              38 (46.9)       151 (470)     0.984
Body surface area               3 (0.2-50)      2 (0.1-90)     0.458
  (%), median (range)
Fitzpatrick skin types,                                        0.521
    n (%)
  (i) Type III                   13 (16.0)       57 (17.8)
  (ii) Type IV                   57 (70.4)      234 (72.9)
  (iii) Type V                   11 (13.6)       30 (9.3)
Type of vitiligo, n (%)                                        0.618
  (i) Nonsegmental               63 (77.8)      258 (80.4)
  (ii) Segmental                 13 (16.0)       51 (15.9)
  (iii) Focal                     5 (6.2)        12 (3.7)
Initial location, n (%)
  (i) Head and neck              37 (45.7)      143 (44.6)     0.855
  (ii) Trunk                     13 (16.1)       17 (5.3)      0.001
  (iii) Arms                      4 (4.9)        38 (11.8)     0.070
  (iv) Hands                     17 (21.0)      103 (32.1)     0.051
  (v) Legs                       9 (11.1)        23 (7.2)      0.241
  (vi) Feet                       5 (6.2)        12 (3.7)      0.354
Associated diseases, n (%)       28 (34.6)      110 (34.3)     0.959
  (i) Hyperthyroidism             1 (2.6)        15 (9.6)      0.560
  (ii) Hypothyroidism             1 (2.6)        11 (6.7)      0.560
  (iii) Diabetes mellitus         3 (3.7)        14 (4.4)      1.000
  (iv) Allergic rhinitis/         6 (74)         22 (6.9)      0.861
  (v) Alopecia areata             1 (1.2)         9 (2.8)      0.368
  (vi) Halo nevi                  3 (3.7)        19 (5.9)      0.319
Positive results for             16 (25.4)       75 (30.0)     0.472
  anti-microsomal antibody
Positive results for             12 (19.5)       49 (19.8)     0.888
Positive results for ANA         30 (45.5)      117 (45.2)     0.967
TSH level                                                      0.216
  (i) Low                        2 (3.23)        16 (7.31)
  (ii) Normal                   60 (96.77)      195 (89.04)
  (iii) High                       0(0)          8 (3.65)
DLQI, median (range)             7 (0-26)        5 (0-26)      0.001

Table 2: Characteristics of itch in vitiliginous lesions.

Characteristics                                   n (%)

Prevalence of itch                            81 (20.2), 95%
                                              CI (16.3-24.4)
Intensity of itch in vitiligo (VAS),             5(1-10)
  median (range)
Intensity of itch in insect bite (VAS),          5(0-10)
  median (range)
Frequency of itch
  (i) Always                                     4 (4.9)
  (ii) Often                                    77 (95.1)
Aggravating factors
  (i) Hot environment                           40 (49.4)
  (ii) Dry skin                                 47 (58.0)
  (iii) Sunlight                                20 (24.7)
  (iv) Cold environment                         13 (16.1)
  (v) Seafood                                    7 (8.6)
Alleviating factors
  (i) Topical corticosteroids                   45 (55.6)
  (ii) Shower                                   31 (38.2)
  (iii) Cold environment                        21 (25.9)
  (iv) Oral antihistamines                       8 (9.9)
  (v) Phototherapy                               5 (6.2)
Relationship of itch and
    onset of lesion(s)
  (i) Itch before onset                         39 (48.1)
    Day, median (range)                          3 (1-60)
  (ii) Itch after onset                         37 (45.7)
    Day, median (range)                         1 (0.5-30)
  (iii) Uncertain                                5 (6.2)
Itch sensory qualities
  (i) Tingling                                  51 (63.0)
  (ii) Crawling                                  5 (6.2)
  (iii) Burning                                  7 (8.7)
  (iv) Pinching                                  1 (1.2)
  (v) Tingling + crawling                        5 (6.2)
  (vi) Tingling + burning                        4 (4.9)
  (vii) Tingling + electric discharge            1 (1.2)
  (viii) Tingling + tickling                     2 (2.5)
  (ix) Tingling + crawling + burning             4 (4.9)
  (x) Crawling + electric discharge              1 (1.2)
Severity of itch
  (i) Mild itch (VAS > 0 to <3.0)               23 (28.4)
  (ii) Moderate itch (VAS [greater than or      35 (43.2)
    equal to] 3.0 to <70)
  (iii) Severe itch (VAS [greater than or       23 (28.4)
    equal to] 70 to 10).

Table 3: Intensity, sensation of pruritus, and activity and
sleep disturbance between males and females.

Characteristics                   Male, n (%)   Female, n (%)     P

Intensity of pruritus in                                        0.291
    vitiliginous lesion by VAS
  (i) Mild (1-3)                   10 (37.0)      13 (24.1)
  (ii) Moderate (4-6)              12 (44.4)      23 (42.6)
  (iii) Severe (7-10)              5 (18.6)       18 (33.3)
Itch sensory qualities
  (i) Tingling                     24 (88.9)      43 (79.6)     0.365
  (ii) Crawling                     2 (74)        13 (24.1)     0.069
  (iii) Burning                    6 (22.2)       9 (16.7)      0.544
  (iv) Pinching                        0           1 (1.9)      1.000
  (v) Electric discharge            1 (3.7)        1 (1.9)      1.000
  (vi) Tickling                     1 (3.7)        1 (1.9)      1.000
Activity disturbance                                            0.033
  (i) No                           15 (55.6)      17 (31.4)
  (ii) Mild                        8 (29.6)       11 (20.4)
  (iii) Moderate                    2 (74)        15 (27.8)
  (iv) Severe                       2 (7.4)       11 (20.4)
Sleep disturbance                                               0.152
  (i) No                           21 (77.8)      28 (51.9)
  (ii) Mild                        4 (14.8)       14 (25.9)
  (iii) Moderate                    1 (3.7)       6 (11.1)
  (iv) Severe                       1 (3.7)       6 (11.1)

Table 4: Koebner phenomenon (KP) between itch and nonitch groups.

Koebner phenomenon               Itch        Nonitch       P
                               (n = 81)     (n = 321)

KP, n (%)                     50 (67.9)    175 (54.52)   0.243
KP type I                     35 (43.2)    110 (34.3)    0.134
  (i) Cutting/scratching      28 (34.6)     86 (26.8)    0.165
  (ii) Rubbing                 35 (8.7)     24 (7.5)     0.082
  (iii) Chemical/heat/cold     5 (6.2)      16 (5.0)     0.588
  (iv) Pressure                5 (6.2)       8 (2.5)     0.094
  (v) Previous skin disease    4 (4.9)      11 (3.4)     0.521
KP type II                    43 (53.1)    141 (43.9)    0.139
  (i) KP type IIa             19 (23.46)    76 (23.8)    0.967
  (ii) KP type IIb            32 (39.5)     92 (28.9)    0.059
KP type III                    1 (1.23)     4 (1.25)     1.000

Figure 2: Disease activity among patients with itch and Koebner
phenomenon (KP) type IIb.

Disease activity

                           Stable vitiligo   Active vitiligo

Itch without KP type IIb   30 (61.2%) *      19(38.8%) *
Itch with KP type IIb      7(21.9%)          25(78.1%)

*p = 0.001

Note: Table made from bar graph.
COPYRIGHT 2017 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Vachiramon, Vasanop; Onprasert, Woranit; Harnchoowong, Sarawin; Chanprapaph, Kumutnart
Publication:BioMed Research International
Article Type:Report
Date:Jan 1, 2017
Previous Article:Green Tea Extracts Epigallocatechin-3-gallate for Different Treatments.
Next Article:Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |